Abstract
Gynaecological malignancies affect women in low and middle income countries (LMICs) at disproportionately higher rates compared with high income countries (HICs) with little known about variations in access, quality, and outcomes in global cancer care. Our study aims to evaluate international variation in post-operative morbidity and mortality following gynaecological oncology surgery between HIC and LMIC settings. Study design consisted of a multicentre, international prospective cohort study of women undergoing surgery for gynaecological malignancies (NCT04579861). Multilevel logistic regression determined relationships within three-level nested-models of patients within hospitals/countries. We enrolled 1820 patients from 73 hospitals in 27 countries. Minor morbidity (Clavien-Dindo I-II) was 26.5% (178/672) and 26.5% (267/1009), whilst major morbidity (Clavien-Dindo III-V) was 8.2% (55/672) and 7% (71/1009) for LMICs/HICs, respectively. Higher minor morbidity was associated with pre-operative mechanical bowel preparation (OR = 1.474, 95%CI = 1.054-2.061, p = 0.023), longer surgeries (OR = 1.253, 95%CI = 1.066-1.472, p = 0.006), greater blood loss (OR = 1.274, 95%CI = 1.081-1.502, p = 0.004). Higher major morbidity was associated with longer surgeries (OR = 1.37, 95%CI = 1.128-1.664, p = 0.002), greater blood loss (OR = 1.398, 95%CI = 1.175-1.664, p ≤ 0.001), and seniority of lead surgeon, with junior surgeons three times more likely to have a major complication (OR = 2.982, 95%CI = 1.509-5.894, p = 0.002). Of all surgeries, 50% versus 25% were performed by junior surgeons in LMICs/HICs, respectively. We conclude that LMICs and HICs were associated with similar post-operative major morbidity. Capacity to rescue patients from surgical complications is a tangible opportunity for meaningful intervention.
Original language | English |
---|---|
Article number | 5001 |
Journal | Cancers |
Volume | 15 |
Issue number | 20 |
DOIs | |
Publication status | Published - 16 Oct 2023 |
Bibliographical note
AcknowledgmentsWe are grateful to the members of the international steering committee. We acknowledge support provided by a number stakeholders including the European Network of Young Gynae Oncologists (ENYGO), Society of Gynecologic Oncology (SGO) and Target Ovarian Cancer. We are grateful to the study sponsor NHS Grampian and our funders The NHS Grampian Endowment Fund and Medtronic. In addition, we are grateful to all our GO SOAR Collaborators (Supplementary File S3).
Funding
This research was funded by The NHS Grampian Endowment Fund and Medtronic.
Data Availability Statement
Relevant anonymised data can be obtained on reasonable request from the corresponding author.Keywords
- Surgery
- gynaecological oncology
- Morbidity
- mortality
- Collaborative research